Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib Effect on P-gp (Dabigatran PK) in Healthy Subjects
NCT03492437Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- May 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tepotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck KGaA. Primary endpoints: Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time at Day 8, Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity at Day 8 and 1 more. Started May 2018; status: completed.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03492437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492437.